Login / Signup

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.

Yuxiang MaJinhui XueYuanyuan ZhaoYang ZhangYan HuangYunpeng YangWenfeng FangYe GuoQun LiXiaoxiao GeJie SunBangyong ZhangYuhan ZhangJinyuan XiaoLi ZhangHongyun Zhao
Published in: Journal for immunotherapy of cancer (2023)
NCT03733951 .
Keyphrases
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • cancer therapy
  • open label
  • randomized controlled trial
  • drug delivery
  • double blind